140 related articles for article (PubMed ID: 11584024)
1. T cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface.
Buslepp J; Zhao R; Donnini D; Loftus D; Saad M; Appella E; Collins EJ
J Biol Chem; 2001 Dec; 276(50):47320-8. PubMed ID: 11584024
[TBL] [Abstract][Full Text] [Related]
2. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.
Purbhoo MA; Boulter JM; Price DA; Vuidepot AL; Hourigan CS; Dunbar PR; Olson K; Dawson SJ; Phillips RE; Jakobsen BK; Bell JI; Sewell AK
J Biol Chem; 2001 Aug; 276(35):32786-92. PubMed ID: 11438524
[TBL] [Abstract][Full Text] [Related]
3. Dissection of the interaction of the human cytomegalovirus-derived US2 protein with major histocompatibility complex class I molecules: prominent role of a single arginine residue in human leukocyte antigen-A2.
Thilo C; Berglund P; Applequist SE; Yewdell JW; Ljunggren HG; Achour A
J Biol Chem; 2006 Mar; 281(13):8950-7. PubMed ID: 16452487
[TBL] [Abstract][Full Text] [Related]
4. Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules.
Bouvier M; Wiley DC
Proc Natl Acad Sci U S A; 1996 May; 93(10):4583-8. PubMed ID: 8643447
[TBL] [Abstract][Full Text] [Related]
5. Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha.
Gao GF; Willcox BE; Wyer JR; Boulter JM; O'Callaghan CA; Maenaka K; Stuart DI; Jones EY; Van Der Merwe PA; Bell JI; Jakobsen BK
J Biol Chem; 2000 May; 275(20):15232-8. PubMed ID: 10809759
[TBL] [Abstract][Full Text] [Related]
6. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition.
Theodossis A; Guillonneau C; Welland A; Ely LK; Clements CS; Williamson NA; Webb AI; Wilce JA; Mulder RJ; Dunstone MA; Doherty PC; McCluskey J; Purcell AW; Turner SJ; Rossjohn J
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5534-9. PubMed ID: 20212169
[TBL] [Abstract][Full Text] [Related]
7. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.
Kuhns JJ; Batalia MA; Yan S; Collins EJ
J Biol Chem; 1999 Dec; 274(51):36422-7. PubMed ID: 10593938
[TBL] [Abstract][Full Text] [Related]
8. Automatic sequence design of major histocompatibility complex class I binding peptides impairing CD8+ T cell recognition.
Ogata K; Jaramillo A; Cohen W; Briand JP; Connan F; Choppin J; Muller S; Wodak SJ
J Biol Chem; 2003 Jan; 278(2):1281-90. PubMed ID: 12411444
[TBL] [Abstract][Full Text] [Related]
9. Quantum dot/pMHC multimers vs. phycoerythrin/pMHC tetramers for identification of HLA-A*0201-restricted pHBV core antigen18-27-specific T cells.
Zhu J; Huang Y; Su J; He J; Yu Y; Zhao Y; Lu X
Mol Med Rep; 2017 Dec; 16(6):8605-8612. PubMed ID: 28765875
[TBL] [Abstract][Full Text] [Related]
10. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
Dutoit V; Guillaume P; Cerottini JC; Romero P; Valmori D
Eur J Immunol; 2002 Nov; 32(11):3285-93. PubMed ID: 12555674
[TBL] [Abstract][Full Text] [Related]
11. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
12. Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition.
Baxter TK; Gagnon SJ; Davis-Harrison RL; Beck JC; Binz AK; Turner RV; Biddison WE; Baker BM
J Biol Chem; 2004 Jul; 279(28):29175-84. PubMed ID: 15131131
[TBL] [Abstract][Full Text] [Related]
13. CD8 kinetically promotes ligand binding to the T-cell antigen receptor.
Gakamsky DM; Luescher IF; Pramanik A; Kopito RB; Lemonnier F; Vogel H; Rigler R; Pecht I
Biophys J; 2005 Sep; 89(3):2121-33. PubMed ID: 15980174
[TBL] [Abstract][Full Text] [Related]
14. High affinity xenoreactive TCR:MHC interaction recruits CD8 in absence of binding to MHC.
Buslepp J; Kerry SE; Loftus D; Frelinger JA; Appella E; Collins EJ
J Immunol; 2003 Jan; 170(1):373-83. PubMed ID: 12496422
[TBL] [Abstract][Full Text] [Related]
15. Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes.
Mohammed F; Stones DH; Willcox BE
J Immunol Methods; 2019 Jan; 464():47-56. PubMed ID: 30365927
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
17. "Self" to cytotoxic T cells has to be 1,000 or less high affinity nonapeptides per MHC antigen.
Ohno S
Immunogenetics; 1992; 36(1):22-7. PubMed ID: 1375187
[TBL] [Abstract][Full Text] [Related]
18. Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules.
Newberg MH; Ridge JP; Vining DR; Salter RD; Engelhard VH
J Immunol; 1992 Jul; 149(1):136-42. PubMed ID: 1607650
[TBL] [Abstract][Full Text] [Related]
19. HLA-A2 subtypes are functionally distinct in peptide binding and presentation.
Barouch D; Friede T; Stevanović S; Tussey L; Smith K; Rowland-Jones S; Braud V; McMichael A; Rammensee HG
J Exp Med; 1995 Dec; 182(6):1847-56. PubMed ID: 7500030
[TBL] [Abstract][Full Text] [Related]
20. MHC recognition by hapten-specific HLA-A2-restricted CD8+ CTL.
Gagnon SJ; Wang Z; Turner R; Damirjian M; Biddison WE
J Immunol; 2003 Sep; 171(5):2233-41. PubMed ID: 12928367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
